Uncategorized
Interleukin-1 inhibitor meets efficacy criteria in study of dry eye disease
An interleukin-1 receptor antagonist met efficacy criteria in a phase 1b/2a study involving patients with dry eye disease, Eleven Biotherapeutics announced in a press release.Compared with baseline, topical ocular administration of EBI-005 resulted in statistically significant improvements in signs and symptoms of dry eye disease and showed a differential effect between subjects who received EBI-005 and subjects who received placebo.